Sarcopenia and frailty: new challenges for clinical practice
Sarcopenia and frailty: new challenges for clinical practice
复制标题
DOI：
10.7861/clinmedicine.16-5-455
复制
发表时间：
2016-10-01
影响因子：
4.4
通讯作者：
Sayer, Avan Aihie
中科院分区：
文献类型：
--
作者：
Dodds, Richard;Sayer, Avan Aihie
肌肉减少症和虚弱是随着年龄的增长而变得越来越普遍的重要病症。肌肉减少症是指肌肉质量和功能的丧失，而虚弱可以定义为与对压力源的脆弱性增加相关的多系统损伤。这两种情况之间存在重叠，特别是在虚弱表型的身体方面：低握力、步态速度和肌肉质量。这些措施与广泛的衰老结果相关，并且可以在临床环境中进行评估。在干预方面，有证据表明抗阻锻炼计划是有益的，尽管这些计划可能并不总是可行。对现有药物和新药物以及膳食补充剂的使用进行了大量研究。最后，为了预防或延缓这些病症的发展，另一种方法是考虑整个生命过程中的病因因素。
Sarcopenia and frailty are important conditions that become increasingly prevalent with age. Sarcopenia is the loss of muscle mass and function, and frailty can be defined as multi-system impairment associated with increased vulnerability to stressors. There is overlap between the two conditions, especially in terms of the physical aspects of the frailty phenotype: low grip strength, gait speed and muscle mass. These measures have been associated with a wide range of ageing outcomes and can be assessed in the clinical setting. In terms of intervention, there is evidence for the benefit of resistance exercise programmes, although these may not always be feasible. Considerable research into the use of medicines, both existing and new, as well as dietary supplements is ongoing. Finally in order to prevent or delay the development of these conditions, an additional approach is to consider aetiological factors operating across the life course.